CytoReason
The First Cell-Centered Computational Model of Human Disease
114 employees · est. 2016 · Israel
CytoReason is the older company (2016 vs 2021); CytoReason is the larger of the two.
Side-by-Side Comparison
| Metric | CytoReason | Protai |
|---|---|---|
| Founded | ||
| Founded | 2016 older | 2021 |
| Headquarters | ||
| Headquarters | Israel | Israel |
| Employees | ||
| Employees | 114 larger | 29 |
| Industry | ||
| Industry | Biotechnology | AI, Biotechnology, Life Sciences |
| Funding Stage | ||
| Funding Stage | Series B | Seed |
| Total Funding | ||
| Total Funding | $118.50M | $20.00M |
| Funding Rounds | ||
| Funding Rounds | 8 | 2 |
| Services | ||
| Services | Disease Model Development, Drug Mechanism Mapping, Portfolio Optimization Platform, Real-time Data Analysis | Structural Proteomics Integration, AI-Driven Drug Discovery, Pipeline Development, End-to-End Drug Discovery Collaboration, AIMS™ Platform Utilization |
| Target Customers | ||
| Target Customers | Pharmaceutical Companies, Biopharma Researchers, Drug Development Scientists, Healthcare Executives | Pharmaceutical Companies, Biotech Firms, Research Institutions, Healthcare Innovators, Partnering Enterprises |
| Taxonomy | ||
| Taxonomy | AI Platform, Computational Disease Models, Biopharma Decision-Making, Drug Development Life Cycle, Target Discovery, Indication Prioritization, Patient Stratification, Biomarker Discovery, Immune System Research, Cancer Immunotherapy, Tissue And Cell Mapping, Data-Driven Drug Discovery, In Silico Drug Development, Inflammatory Bowel Disease, Atopic Dermatitis | Proteomics, AI Drug Discovery, End-to-End AI Platform, Cellular Function Analysis, Biological Insights, Complex Disease Combat, Protein Level Mapping, Drug Candidate Creation, Drug Discovery Facilitation, Advanced Drug Discovery, Disease Mapping, Molecular Biology, Pharmaceutical Innovation, Biotech |
| Website | ||
| Website | cytoreason.com | protai.bio |
About CytoReason
CytoReason, founded in 2016 and headquartered in Israel, stands at the forefront of the Biotechnology industry with its pioneering platform, described by its slogan as "The First Cell-Centered Computational Model of Human Disease." This tech innovator revitalizes biopharma’s approach by transitionin...
About Protai
Protai, founded in 2021 and headquartered in Israel, leverages cutting-edge technologies in AI, Biotechnology, and Life Sciences to revolutionize drug discovery. By utilizing an AI-based platform, Protai delves into the proteomic landscape to map diseases at the protein level, offering a novel appro...
We will tell you when either one moves
BounceWatch watches CytoReason and Protai for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at CytoReason and Protai — by email.
Frequently Asked Questions
Compare CytoReason with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at CytoReason on 15 Jun 2026, and Protai on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.